@article{7ea7c861fabd42da8ba225d9031e8afe,
title = "Reduction in comorbid conditions over 5 years following bariatric surgery in medicaid and commercially insured patients",
abstract = "Objective: This study sought to determine changes in the prevalence of comorbid disease following bariatric surgery in Medicaid patients compared with commercially insured patients. Methods: Data were obtained from the Longitudinal Assessment of Bariatric Surgery, an observational cohort study of adults undergoing bariatric surgery at one of six geographically diverse centers in the United States. A total of 1,201 patients who underwent Roux-en-Y gastric bypass with 5 years of follow-up were identified. Poisson mixed models were used to estimate relative risks (RRs) and compare changes in common comorbidities between insurance groups within 0-1 and 1-5 years post surgery. Propensity scores were used to achieve balance in the baseline comorbidity burden between Medicaid and commercial patients. Results: In the first year, risk of all six comorbidities decreased substantially over time in both groups, ranging from a 32% to a 69% decrease from baseline. After 1 year post surgery, the risk of disease was stable in both groups (RRs ranged from 1.0 to 1.1). After propensity score weighting, the RRs in the first year were more similar in magnitude, while the RRs in the 1- to 5-year period were unchanged. Conclusions: These results suggest that Medicaid patients experience a medium-term reduction in comorbid disease after bariatric surgery.",
author = "Erin Takemoto and Wolfe, {Bruce M.} and Nagel, {Corey L.} and Janne Boone-Heinonen",
note = "Funding Information: Funding agencies: The Longitudinal Assessment of Bariatric Surgery (LABS-2) study was funded by a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Grant numbers: Data Coordinating Center, U01DK066557; Columbia-Presbyterian, U01-DK66667 (in collaboration with Cornell University Medical Center Clinical and Translational Science Center, grant UL1-RR024996); University of Washington, U01-DK66568 (in collaboration with Clinical and Translational Science Center, grant M01 RR-00037); Neuropsychiatric Research Institute, U01-DK66471; East Carolina University, U01-DK66526; University of Pittsburgh Medical Center, U01-DK66585 (in collaboration with Clinical and Translational Science Institute, grant UL1-RR024153); and Oregon Health & Science University, U01-DK66555. Disclosure: The authors declared no conflict of interest. Clinical trial registration: ClinicalTrials.gov identifier NCT00465829. Additional Supporting Information may be found in the online version of this article. Received: 25 June 2018; Accepted: 21 August 2018; Published online 25 October 2018. doi:10.1002/oby.22312 Funding Information: LABS-2 was funded by a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Grant numbers: Data Coordinating Center, U01 DK066557; Columbia-Presbyterian, U01- DK66667 (in collaboration with Cornell University Medical Center CTSC, grant UL1-RR024996); University of Washington, U01-DK66568 (in collaboration with CTRC, grant M01 RR-00037); Neuropsychiatric Research Institute, U01- DK66471; East Carolina University, U01-DK66526; University of Pittsburgh Medical Center, U01-DK66585 (in collaboration with CTRC, grant UL1-RR024153); and Oregon Health & Science University, U01-DK66555. Publisher Copyright: {\textcopyright} 2018 The Obesity Society",
year = "2018",
month = nov,
doi = "10.1002/oby.22312",
language = "English (US)",
volume = "26",
pages = "1807--1814",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "11",
}